The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan, GI-screen: Efficient identification of cancer genome alterations in advanced gastric cancer.
 
Shigenori Kadowaki
Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
 
Kohei Shitara
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Satoshi Yuki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Shuichi Hironaka
No Relationships to Disclose
 
Takeshi Kato
Speakers' Bureau - Chugai Pharma; Lilly; Takeda; Yakult Pharmaceutical
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takeshi Kajiwara
No Relationships to Disclose
 
Naoki Izawa
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck Serono (Inst)
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Daisuke Naruge
Research Funding - Astellas Pharma (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Eisai; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroshi Saeki
No Relationships to Disclose
 
Toshihiro Kudo
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Haruhiko Cho
No Relationships to Disclose
 
Takao Tamura
No Relationships to Disclose
 
Hiromichi Ebi
No Relationships to Disclose
 
Shogo Nomura
Employment - Asahi Kasei (I)
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)